Jensen Dennis M, Ohning Gordon V, Kovacs Thomas O G, Ghassemi Kevin A, Jutabha Rome, Dulai Gareth S, Machicado Gustavo A
CURE Hemostasis Research Group of the CURE Digestive Diseases Research Center, Divisions of Digestive Diseases and Departments of Medicine, Ronald Reagan University of California at Los Angeles Medical Center, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, Calif, USA; West Los Angeles Veterans Administration Medical Center, Los Angeles, Calif, USA.
CURE Hemostasis Research Group of the CURE Digestive Diseases Research Center, Divisions of Digestive Diseases and Departments of Medicine, Ronald Reagan University of California at Los Angeles Medical Center, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, Calif, USA.
Gastrointest Endosc. 2016 Jan;83(1):129-36. doi: 10.1016/j.gie.2015.07.012. Epub 2015 Aug 28.
For more than 4 decades endoscopists have relied on ulcer stigmata for risk stratification and as a guide to hemostasis. None used arterial blood flow underneath stigmata to predict outcomes. For patients with severe peptic ulcer bleeding (PUB), we used a Doppler endoscopic probe (DEP) for (1) detection of blood flow underlying stigmata of recent hemorrhage (SRH), (2) quantitating rates of residual arterial blood flow under SRH after visually directed standard endoscopic treatment, and (3) comparing risks of rebleeding and actual 30-day rebleed rates for spurting arterial bleeding (Forrest [F] IA) and oozing bleeding (F IB).
Prospective cohort study of 163 consecutive patients with severe PUB and different SRH.
All blood flow detected by the DEP was arterial. Detection rates were 87.4% in major SRH-spurting arterial bleeding (F IA), non-bleeding visible vessel (F IIA), clot (F IIB)-and were significantly lower at 42.3% (P < .0001) for an intermediate group of oozing bleeding (F IB) or flat spot (F IIC). For spurting bleeding (F IA) versus oozing (F IB), baseline DEP arterial flow was 100% versus 46.7%, residual blood flow detected after endoscopic hemostasis was 35.7% versus 0%, and 30-day rebleed rates were 28.6% versus 0% (all P < .05).
(1) For major SRH versus oozing or spot, the arterial blood flow detection rate by the DEP was significantly higher, indicating a higher rebleed risk. (2) Before and after endoscopic treatment, spurting (F IA) PUB had significantly higher rates of blood flow detection than oozing (F IB) PUB and a significantly higher 30-day rebleed rate. (3) The DEP is recommended as a new endoscopic guide with SRH to improve risk stratification and potentially definitive hemostasis for PUB.
四十多年来,内镜医师一直依靠溃疡特征进行风险分层并指导止血。此前没有人利用溃疡特征下方的动脉血流来预测预后。对于严重消化性溃疡出血(PUB)患者,我们使用多普勒内镜探头(DEP)来:(1)检测近期出血(SRH)特征下方的血流;(2)在直视下进行标准内镜治疗后,定量检测SRH下方残余动脉血流的速率;(3)比较喷射性动脉出血(Forrest [F] IA)和渗血(F IB)的再出血风险及实际30天再出血率。
对163例连续的患有严重PUB且具有不同SRH的患者进行前瞻性队列研究。
DEP检测到的所有血流均为动脉血流。在主要SRH(喷射性动脉出血,F IA)、非出血可见血管(F IIA)、血凝块(F IIB)中,检测率为87.4%;而在渗血(F IB)或平坦斑(F IIC)这一中间组中,检测率显著较低,为42.3%(P <.0001)。对于喷射性出血(F IA)与渗血(F IB),基线DEP动脉血流分别为100%和46.7%,内镜止血后检测到的残余血流分别为35.7%和0%,30天再出血率分别为28.6%和0%(所有P <.05)。
(1)对于主要SRH与渗血或斑点状出血,DEP的动脉血流检测率显著更高,表明再出血风险更高。(2)在内镜治疗前后,喷射性(F IA)PUB的血流检测率显著高于渗血(F IB)PUB,且30天再出血率显著更高。(3)推荐将DEP作为一种新的内镜指导手段用于SRH,以改善PUB的风险分层并可能实现确定性止血。